Nebulised Tranexamic Acid for Acute Non-Massive Haemoptysis
For acute non-massive haemoptysis, administer 500 mg tranexamic acid in 5 mL normal saline via nebulisation every 8 hours for 2 days, with the option to continue up to 8 days if bleeding persists.
Dosing Protocol
The evidence-based regimen for nebulised tranexamic acid is:
- Dose: 500 mg tranexamic acid in 5 mL solution
- Frequency: Every 8 hours (three times daily)
- Duration: 2 days initially, extendable to 8 days based on clinical response
- Administration: Standard jet nebuliser over approximately 10-15 minutes
This dosing is supported by the most recent randomised controlled trials 1, 2, 3 and represents the most commonly studied and effective regimen.
Clinical Efficacy
Nebulised tranexamic acid achieves haemoptysis cessation as effectively as intravenous administration, with significant advantages. The 2026 RCT demonstrated complete cessation of haemoptysis in 5.70 ± 4.80 hours with nebulised TXA versus 7.39 ± 5.02 hours with IV TXA (P = 0.25), showing non-inferiority 1. More importantly, nebulised TXA was 3.85 times more likely to achieve haemoptysis cessation compared to placebo across pooled RCTs 4.
The 2025 TXA-NEB trial showed that nebulised TXA achieved:
- 63.9% reduction in bleeding frequency at day 1 (vs 39.8% with placebo, P = 0.012)
- 73.4% reduction in bleeding quantity at day 1 (vs 51.7% with placebo, P = 0.024)
- 63% resolution rate versus 24.1% with placebo (P = 0.003) 2
Advantages Over Systemic Administration
Nebulised delivery provides localised haemostatic action directly at the bleeding site with minimal systemic absorption, reducing thrombotic risk while maintaining efficacy. Patients receiving nebulised TXA required 43% fewer invasive pulmonary procedures compared to other treatments 4. The 2018 RCT demonstrated that 96% of patients achieved resolution within 5 days with nebulised TXA versus 50% with placebo, with shorter hospital stays (5.7 vs 7.8 days, P = 0.046) and zero patients requiring interventional bronchoscopy or embolisation versus 18.2% in the placebo group 3.
Safety Profile
Nebulised tranexamic acid demonstrates excellent safety with no serious adverse events reported across all studies. Minor side effects include:
- Cough (37.5% of patients)
- Throat irritation (33.9% of patients)
These effects are self-limiting and comparable to placebo 2. Critically, no venous thromboembolism or systemic thrombotic complications have been documented with nebulised administration 1, 5, 3, contrasting with the theoretical concerns of systemic TXA.
Integration with Standard Care
Recent 2025 French emergency medicine guidelines support tranexamic acid use in bleeding scenarios, including epistaxis and oral bleeding, with the same indications regardless of anticoagulation status 6. While these guidelines primarily address IV/topical routes, the principle of antifibrinolytic therapy applies equally to pulmonary haemorrhage.
Nebulised TXA serves as effective bridging therapy while arranging definitive interventions such as bronchial artery embolisation or bronchoscopy 2, 7. It should be initiated immediately upon presentation with non-massive haemoptysis (defined as <200 mL/24 hours) alongside:
- Airway assessment and protection
- Haemodynamic stabilisation
- CT angiography for bleeding localisation
- Identification of underlying aetiology (tuberculosis, malignancy, bronchiectasis)
Contraindications and Precautions
Do not use nebulised tranexamic acid in:
- Massive haemoptysis (>200 mL/24 hours) requiring immediate invasive intervention
- Known hypersensitivity to tranexamic acid
- Active thromboembolic disease (though systemic absorption is minimal)
Bronchospasm is rare but manageable with short-acting bronchodilators if it occurs 5.
Comparison to IV Administration
While IV tranexamic acid follows established trauma dosing (1 g bolus over 10 minutes, then 1 g over 8 hours) 8, this regimen is designed for systemic coagulopathy, not localised pulmonary bleeding. The FDA-approved IV dosing for other indications is 10 mg/kg 9, but nebulised administration at 500 mg every 8 hours provides superior targeted delivery with equivalent or better outcomes for non-massive haemoptysis 1.
Clinical Algorithm
- Confirm non-massive haemoptysis (<200 mL/24 hours, haemodynamically stable)
- Initiate nebulised TXA immediately: 500 mg in 5 mL every 8 hours
- Monitor bleeding volume at 8-hour intervals
- Continue for 2 days minimum, extend to 8 days if bleeding persists
- Arrange CT angiography and bronchoscopy for definitive diagnosis
- Escalate to interventional procedures (BAE, surgery) only if bleeding continues despite TXA or if massive haemoptysis develops
The evidence strongly supports nebulised tranexamic acid as first-line pharmacological therapy for non-massive haemoptysis, offering rapid bleeding control, reduced need for invasive procedures, and excellent safety—making it an ideal emergency department intervention 1, 2, 4, 3, 7, 10.